questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Tumeurs épithéliales épidermoïdes et glandulaires
Tumeurs canalaires, lobulaires et médullaires
Tumeurs canalaires, lobulaires et médullaires : Questions médicales fréquentes
Diagnostic
5
Tumeurs lobulaires
Biopsie
Mammographie
Tumeurs médullaires
IRM
Échographie
Marqueurs tumoraux
Néoplasmes
Diagnostic
Tumeurs canalaires
IRM
Mammographie
Tests génétiques
Antécédents familiaux
Néoplasmes
Symptômes
5
Tumeurs lobulaires
Symptômes
Cancer du sein
Tumeurs médullaires
Douleur
Néoplasmes
Tumeurs canalaires
Écoulement mammaire
Symptômes
Symptômes
Fatigue
Néoplasmes
Changements cutanés
Tumeurs
Symptômes
Prévention
5
Prévention
Tumeurs lobulaires
Mode de vie sain
Dépistage
Mammographie
Prévention
Vaccins
Néoplasmes
Prévention
Tabagisme
Facteurs de risque
Prévention
Alimentation
Prévention
Néoplasmes
Traitements
5
Tumeurs lobulaires
Chirurgie
Chimiothérapie
Tumeurs médullaires
Radiothérapie
Chirurgie
Tumeurs canalaires
Médicaments
Thérapies ciblées
Chimiothérapie
Néoplasmes
Traitement
Essais cliniques
Traitements expérimentaux
Néoplasmes
Complications
5
Complications
Récidive
Néoplasmes
Tumeurs médullaires
Métastases
Néoplasmes
Effets secondaires
Traitements
Néoplasmes
Suivi médical
Complications
Soutien psychologique
Qualité de vie
Complications
Néoplasmes
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Radiations
Obésité
Facteurs de risque
Néoplasmes
Hormones
Facteurs de risque
Néoplasmes
Âge
Facteurs de risque
Néoplasmes
Mode de vie
Facteurs de risque
Néoplasmes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs canalaires, lobulaires et médullaires : Questions médicales les plus fréquentes",
"headline": "Tumeurs canalaires, lobulaires et médullaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs canalaires, lobulaires et médullaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-15",
"dateModified": "2026-08-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs canalaires, lobulaires et médullaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs épithéliales épidermoïdes et glandulaires",
"url": "https://questionsmedicales.fr/mesh/D009375",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs épithéliales épidermoïdes et glandulaires",
"code": {
"@type": "MedicalCode",
"code": "D009375",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Carcinome canalaire",
"alternateName": "Carcinoma, Ductal",
"url": "https://questionsmedicales.fr/mesh/D044584",
"about": {
"@type": "MedicalCondition",
"name": "Carcinome canalaire",
"code": {
"@type": "MedicalCode",
"code": "D044584",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615.132"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Carcinome intracanalaire non infiltrant",
"alternateName": "Carcinoma, Intraductal, Noninfiltrating",
"url": "https://questionsmedicales.fr/mesh/D002285",
"about": {
"@type": "MedicalCondition",
"name": "Carcinome intracanalaire non infiltrant",
"code": {
"@type": "MedicalCode",
"code": "D002285",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615.275"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Maladie de Paget du sein",
"alternateName": "Paget's Disease, Mammary",
"url": "https://questionsmedicales.fr/mesh/D010144",
"about": {
"@type": "MedicalCondition",
"name": "Maladie de Paget du sein",
"code": {
"@type": "MedicalCode",
"code": "D010144",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615.275.625"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Maladie de Paget extramammaire",
"alternateName": "Paget Disease, Extramammary",
"url": "https://questionsmedicales.fr/mesh/D010145",
"about": {
"@type": "MedicalCondition",
"name": "Maladie de Paget extramammaire",
"code": {
"@type": "MedicalCode",
"code": "D010145",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615.660"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Papillome intracanalaire",
"alternateName": "Papilloma, Intraductal",
"url": "https://questionsmedicales.fr/mesh/D018300",
"about": {
"@type": "MedicalCondition",
"name": "Papillome intracanalaire",
"code": {
"@type": "MedicalCode",
"code": "D018300",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615.670"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs canalaires, lobulaires et médullaires",
"alternateName": "Neoplasms, Ductal, Lobular, and Medullary",
"code": {
"@type": "MedicalCode",
"code": "D018299",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Steffi Oesterreich",
"url": "https://questionsmedicales.fr/author/Steffi%20Oesterreich",
"affiliation": {
"@type": "Organization",
"name": "Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA."
}
},
{
"@type": "Person",
"name": "Adrian V Lee",
"url": "https://questionsmedicales.fr/author/Adrian%20V%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA."
}
},
{
"@type": "Person",
"name": "Azadeh Nasrazadani",
"url": "https://questionsmedicales.fr/author/Azadeh%20Nasrazadani",
"affiliation": {
"@type": "Organization",
"name": "Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. anasrazadani1@mdanderson.org."
}
},
{
"@type": "Person",
"name": "Jennifer M Atkinson",
"url": "https://questionsmedicales.fr/author/Jennifer%20M%20Atkinson",
"affiliation": {
"@type": "Organization",
"name": "Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA."
}
},
{
"@type": "Person",
"name": "Priscilla F McAuliffe",
"url": "https://questionsmedicales.fr/author/Priscilla%20F%20McAuliffe",
"affiliation": {
"@type": "Organization",
"name": "Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.",
"datePublished": "2024-08-13",
"url": "https://questionsmedicales.fr/article/39138705",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.15295"
}
},
{
"@type": "ScholarlyArticle",
"name": "Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention.",
"datePublished": "2024-02-19",
"url": "https://questionsmedicales.fr/article/38398228",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cancers16040837"
}
},
{
"@type": "ScholarlyArticle",
"name": "Guideline-Concordant Surgical Care for Lobular Versus Ductal Inflammatory Breast Cancer.",
"datePublished": "2024-06-17",
"url": "https://questionsmedicales.fr/article/38886328",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-024-15540-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma.",
"datePublished": "2023-09-11",
"url": "https://questionsmedicales.fr/article/37697031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10549-023-07051-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Volumetric analysis of the terminal ductal lobular unit architecture and cell phenotypes in the human breast.",
"datePublished": "2024-10-04",
"url": "https://questionsmedicales.fr/article/39368089",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.celrep.2024.114837"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs épithéliales épidermoïdes et glandulaires",
"item": "https://questionsmedicales.fr/mesh/D009375"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs canalaires, lobulaires et médullaires",
"item": "https://questionsmedicales.fr/mesh/D018299"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs canalaires, lobulaires et médullaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Comment diagnostiquer une tumeur lobulaire ?\nQuels tests sont utilisés pour les tumeurs médullaires ?\nLes marqueurs tumoraux sont-ils utiles ?\nQuelle imagerie pour les tumeurs canalaires ?\nLes examens génétiques sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D018299#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Quels sont les symptômes d'une tumeur lobulaire ?\nComment se manifeste une tumeur médullaire ?\nLes tumeurs canalaires causent-elles des symptômes ?\nY a-t-il des symptômes généraux à surveiller ?\nLes changements cutanés sont-ils un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D018299#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Comment prévenir les tumeurs lobulaires ?\nLes dépistages réguliers sont-ils importants ?\nY a-t-il des vaccins contre ces tumeurs ?\nLe tabagisme influence-t-il le risque ?\nL'alimentation joue-t-elle un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D018299#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Quels traitements pour les tumeurs lobulaires ?\nLa radiothérapie est-elle efficace pour les tumeurs médullaires ?\nQuels médicaments sont utilisés pour les tumeurs canalaires ?\nLa chimiothérapie est-elle nécessaire ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D018299#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Quelles complications peuvent survenir ?\nLes tumeurs médullaires causent-elles des métastases ?\nY a-t-il des effets secondaires des traitements ?\nComment gérer les complications ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D018299#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs canalaires, lobulaires et médullaires",
"description": "Quels sont les principaux facteurs de risque ?\nLe surpoids est-il un facteur de risque ?\nLes hormones influencent-elles le risque ?\nL'âge est-il un facteur déterminant ?\nLe mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018299#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur lobulaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen clinique, une mammographie et une biopsie sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les tumeurs médullaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie, l'IRM et la biopsie sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les marqueurs tumoraux sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains marqueurs peuvent aider à évaluer le type et le stade de la tumeur."
}
},
{
"@type": "Question",
"name": "Quelle imagerie pour les tumeurs canalaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La mammographie et l'IRM sont les principales méthodes d'imagerie."
}
},
{
"@type": "Question",
"name": "Les examens génétiques sont-ils recommandés ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, surtout si des antécédents familiaux de cancer existent."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une tumeur lobulaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des masses palpables et des changements dans la peau du sein."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une tumeur médullaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer des douleurs, des masses et des modifications des tissus environnants."
}
},
{
"@type": "Question",
"name": "Les tumeurs canalaires causent-elles des symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des écoulements mammaires et des douleurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes généraux à surveiller ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, perte de poids et fièvre peuvent être des signes d'alerte."
}
},
{
"@type": "Question",
"name": "Les changements cutanés sont-ils un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des rougeurs ou des modifications de la peau peuvent indiquer une tumeur."
}
},
{
"@type": "Question",
"name": "Comment prévenir les tumeurs lobulaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, y compris une alimentation équilibrée et l'exercice, aide."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils importants ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mammographies régulières peuvent détecter les tumeurs précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins contre ces tumeurs ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour ces néoplasmes."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour plusieurs types de cancers."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en fruits et légumes peut réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Quels traitements pour les tumeurs lobulaires ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Chirurgie, radiothérapie et chimiothérapie sont des options de traitement."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace pour les tumeurs médullaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent utilisée après la chirurgie pour réduire le risque de récidive."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour les tumeurs canalaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de l'aromatase et les thérapies ciblées peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle nécessaire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend du stade et du type de tumeur, souvent pour les cas avancés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques peuvent offrir des options innovantes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la récidive, la propagation et des effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Les tumeurs médullaires causent-elles des métastases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent se propager à d'autres organes si non traitées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, fatigue, nausées et immunosuppression sont fréquents."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un soutien psychologique sont essentiels."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir un impact significatif sur la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Antécédents familiaux, âge avancé et exposition aux radiations sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à un risque accru de plusieurs cancers, y compris les tumeurs mammaires."
}
},
{
"@type": "Question",
"name": "Les hormones influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements hormonaux peuvent augmenter le risque de tumeurs mammaires."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur déterminant ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de développer ces tumeurs augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 03/08/2026
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Magee Women's Hospital, Suite 4628, 300 Halket Street, Pittsburgh, PA, USA.
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
6 publications dans cette catégorie
Affiliations :
Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Magee Women's Hospital, Suite 4628, 300 Halket Street, Pittsburgh, PA, USA.
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
4 publications dans cette catégorie
Affiliations :
Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. anasrazadani1@mdanderson.org.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
4 publications dans cette catégorie
Affiliations :
Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
4 publications dans cette catégorie
Affiliations :
Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
4 publications dans cette catégorie
Affiliations :
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Magee Women's Hospital, Suite 4628, 300 Halket Street, Pittsburgh, PA, USA.
NSABP Foundation, Inc, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Department of Epidemiology, Faculty of Public Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Magee-Women's Research Institute and Women's Cancer Research Center, Pittsburgh, PA, USA.
Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
3 publications dans cette catégorie
Affiliations :
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. reisfilj@mskcc.org tking7@bwh.harvard.edu.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
2 publications dans cette catégorie
Affiliations :
Breast Imaging Division, Radiology Department, (IEO) European Institute of Oncology IRCCS, 20141 Milan, Italy.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
2 publications dans cette catégorie
Affiliations :
Breast Imaging Division, Radiology Department, (IEO) European Institute of Oncology IRCCS, 20141 Milan, Italy.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
2 publications dans cette catégorie
Affiliations :
Division of Pathology, (IEO) European Institute of Oncology IRCCS, 20141 Milan, Italy.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
2 publications dans cette catégorie
Affiliations :
Data Management, (IEO) European Institute of Oncology IRCCS, 20141 Milan, Italy.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
2 publications dans cette catégorie
Affiliations :
Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
2 publications dans cette catégorie
Affiliations :
Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA.
Publications dans "Tumeurs canalaires, lobulaires et médullaires" :
Categorizing breast neoplasia as ductal or lobular is a daily exercise that relies on a combination of histologic and immunohistochemical tools. The historically robust link between loss of the E-cadh...
This retrospective study investigates the histopathological outcomes, upgrade rates, and disease-free survival (DFS) of high-risk breast lesions, including atypical ductal hyperplasia (ADH or DIN1b) a...
Quality of surgical care is understudied for lobular inflammatory breast cancer (IBC), which is less common, more chemotherapy-resistant, and more mammographically occult than ductal IBC. We compared ...
Female individuals with cT4dM0 lobular and ductal IBC were identified in the National Cancer Database (NCDB) from 2010-2019. Modified radical mastectomy receipt was identified via codes for "modified ...
A total of 1456 lobular and 10,445 ductal IBC patients were identified; 599 (41.1%) with lobular and 4859 (46.5%) with ductal IBC underwent MRMs (p = 0.001). Patients with lobular IBC included a highe...
Lobular IBC patients were more likely to present with node-negative disease and less likely to be node-negative at surgery, despite having fewer, and more frequently no, lymph nodes examined versus du...
Invasive lobular carcinoma (ILC) is a distinct histological subtype of breast cancer that can make early detection with mammography challenging. We compared imaging performance of digital breast tomos...
We included screening exams (DM; n = 1,715,249 or DBT; n = 414,793) from 2011 to 2018 among 839,801 women in the Breast Cancer Surveillance Consortium. Examinations were followed for one year to ascer...
Unadjusted CDR per 1000 mammograms of ILC overall was 0.33 (95%CI: 0.30-0.36) for DM; 0.45 (95%CI: 0.39-0.52) for DBT, and for women with dense breasts- 0.33 (95%CI: 0.29-0.37) for DM and 0.54 (95%CI:...
DBT was associated with higher CDR for ILC, IDC, and IMC for women with dense breasts. Early detection of ILC with DBT may improve outcomes for this distinct clinical entity....
The major lactiferous ducts of the human breast branch out and end at terminal ductal lobular units (TDLUs). Despite their functional and clinical importance, the three-dimensional (3D) architecture o...
This is a secondary data analysis of the TIPPING study, which included 1,121 patients with stage I-III breast cancer who had enumeration of CTCs (by either CellSearch or immunomagnetic enrichment and ...
Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk...
A systematic search of literature from 2000 was performed to identify studies reporting BC as an outcome following core-needle or excision biopsy histology diagnosis of ADH, ALH, LCIS, lobular neoplas...
Seventy studies reporting on 47,671 subjects met eligibility criteria. BC incidence at five years post-diagnosis with a high-risk lesion was estimated to be 9.3 % (95 % CI 6.9-12.5 %) for LCIS, 6.6 % ...
Our findings demonstrate increased BC risk sustained over time since initial diagnosis of high-risk breast lesions, varying by lesion type, with relatively less evidence for FEA....
Breast cancer (BC) is one of the main causes of cancer-related mortality among women. For clinical management to help patients survive longer and spend less time on treatment, early and precise cancer...
This is a retrospective study. The IDC of 30 and ILC of 28 patients from Dukes breast cancer MRI data set of The Cancer Imaging Archive (TCIA), were included. The RF categories such as shape based, Gr...
Ten DCE MRI-based RFs used in our study showed a significant difference (p <0.001) between IDC and ILC. We noticed that DCE RF, such as Gray level run length matrix (GLRLM) gray level variance (sensit...
MRI-based RF derived from DCE sequences can be used in clinical settings to differentiate malignant lesions of the breast, such as IDC and ILC, without requiring intrusive procedures....
Medullary breast carcinoma (MBC) is a rare type of breast cancer. Our study aimed to compare the differences in clinical characteristics and prognosis between MBC and invasive ductal carcinoma (IDC), ...
A total of 179,613 patients from the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2015, including 596 MBC patients, were analyzed using the Kaplan-Meier method and propensit...
There were significant differences in the clinical characteristics between MBC and IDC. According to the logrank test, MBC had better OS and CSS than IDC before and after PSM. Cox multivariate analysi...
MBC had better OS and CSS than IDC. Nomograms based on clinicopathological features were sufficiently accurate in predicting the OS and CSS for MBC patients, which can effectively predict the survival...
Invasive lobular carcinoma (ILC) exhibits differences in molecular and biological characteristics compared to invasive ductal carcinoma (IDC). We aim to compare breast cancer-specific survival (BCSS) ...
We used data from the Surveillance, Epidemiology, and End Results database (1992-2020). Logistic regression analyses were conducted to identify factors associated with treatment modalities. We examine...
343,397 patients with IDC and 39,859 patients with ILC were included. Patients with ILC had more advanced stage disease (stage II, 35% vs. 34%; stage III, 16% vs.11%), and higher rate of hormone recep...
Patients with ILC survive better in early years but worse in later years compared to patients with IDC. Future studies are required to identify patients with ILC who are at risk of late recurrence or ...
The results of this study add to the currently conflicting literature of survival of ILC and demonstrate the importance of evaluating novel therapeutic approaches and extended therapy for patients wit...